Evidence map›Paper›PMID 35086771›Full record

ArticleTrends in molecular medicine2022

Bringing gene therapy to where it's needed.

Stefan Radtke, Hans-Peter Kiem

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Bioengineered nanotechnology for nucleic acid delivery.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Stefan RadtkeStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Hans-Peter KiemStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: hkiem@fredhutch.org.

Funding

Novel Gene Editing Approaches for HemoglobinopathiesR01HL136135 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANS-PETER KIEM · 2017 to 2026
$7.7M
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene TherapyR01AI135953 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2018 to 2022
$4.5M
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell DiseaseR01HL130040 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2016 to 2024
$4.3M
NHLBI NIH HHS R01 HL130040NHLBI NIH HHS R01 HL136135NIAID NIH HHS R01 AI135953
6 · The paper itself

Abstract

Gene editing allows the precise modification of cells to correct genetic defects or enhance immunotherapies. A limitation is the delivery of this technology to specific cells or organs. Recently, Banskota et al. reported the use of virus-like particles (VLPs) loaded with gene-editing agents for gene therapy delivery directly inside the body.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic TherapyHumansbase editorsgene therapyin vivo deliverytarget specificity

Identifiers

PMID35086771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.